{"id":37015,"date":"2025-07-09T14:12:51","date_gmt":"2025-07-09T06:12:51","guid":{"rendered":"https:\/\/flcube.com\/?p=37015"},"modified":"2025-07-09T14:12:52","modified_gmt":"2025-07-09T06:12:52","slug":"innovents-dabote-becomes-first-china-originated-kras-g12c-inhibitor-approved-in-macau","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37015","title":{"rendered":"Innovent&#8217;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau"},"content":{"rendered":"\n<p>China-based biopharma leader Innovent Biologics Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent&#8217;s leadership in innovative oncology treatments.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-mechanism-of-action-and-clinical-efficacy\"><strong>Mechanism of Action and Clinical Efficacy<\/strong><\/h4>\n\n\n\n<p>Fulzerasib works by irreversibly modifying the cysteine residues of the KRAS G12C protein mutant through covalent modification. This action inhibits the GTP\/GDP exchange mediated by the protein, downregulates KRAS activation levels, and disrupts downstream signaling pathways. The result is the induction of tumor cell apoptosis and cell cycle arrest, delivering potent anti-tumor effects.<\/p>\n\n\n\n<p>In a Phase II clinical trial involving Chinese patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), fulzerasib demonstrated:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>49.1% Objective Response Rate (ORR)<\/strong>: A robust efficacy profile in targeting KRAS G12C mutations.<\/li>\n\n\n\n<li><strong>9.7 Months Median Progression-Free Survival (mPFS)<\/strong>: Highlighting the drug&#8217;s ability to delay disease progression.<\/li>\n\n\n\n<li><strong>54.4% 12-Month Overall Survival (OS) Rate<\/strong>: Reflecting its potential to improve patient outcomes.<br>The therapy also exhibited a favorable tolerability profile, further enhancing its clinical utility.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-regulatory-and-development-milestones\"><strong>Regulatory and Development Milestones<\/strong><\/h4>\n\n\n\n<p>Fulzerasib received approval from China&#8217;s National Medical Products Administration (NMPA) in April 2022 for the treatment of adult patients with KRAS G12C-mutated NSCLC. This Macau approval expands the drug\u2019s reach within Greater China, reinforcing Innovent\u2019s commitment to advancing innovative cancer therapies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-innovent-s-vision-and-impact\"><strong>Innovent\u2019s Vision and Impact<\/strong><\/h4>\n\n\n\n<p>As a pioneer in China&#8217;s biopharmaceutical industry, Innovent Biologics continues to demonstrate its ability to develop cutting-edge treatments that address unmet medical needs. The approval of Dabote in Macau is a testament to the company\u2019s innovative prowess and its dedication to improving patient care across the region.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37017,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,910,198,15],"class_list":["post-37015","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-1801","tag-innovent-biologics","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent&#039;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent&#039;s leadership in innovative oncology treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37015\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent&#039;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau\" \/>\n<meta property=\"og:description\" content=\"China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent&#039;s leadership in innovative oncology treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37015\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T06:12:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T06:12:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent&#8217;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau\",\"datePublished\":\"2025-07-09T06:12:51+00:00\",\"dateModified\":\"2025-07-09T06:12:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015\"},\"wordCount\":308,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0908.webp\",\"keywords\":[\"Cancer\",\"HKG: 1801\",\"Innovent Biologics\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37015#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37015\",\"name\":\"Innovent's Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0908.webp\",\"datePublished\":\"2025-07-09T06:12:51+00:00\",\"dateModified\":\"2025-07-09T06:12:52+00:00\",\"description\":\"China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent's leadership in innovative oncology treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37015\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0908.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent's Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37015#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent&#8217;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent's Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau - Insight, China&#039;s Pharmaceutical Industry","description":"China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent's leadership in innovative oncology treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37015","og_locale":"en_US","og_type":"article","og_title":"Innovent's Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau","og_description":"China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent's leadership in innovative oncology treatments.","og_url":"https:\/\/flcube.com\/?p=37015","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-09T06:12:51+00:00","article_modified_time":"2025-07-09T06:12:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37015#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37015"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent&#8217;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau","datePublished":"2025-07-09T06:12:51+00:00","dateModified":"2025-07-09T06:12:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37015"},"wordCount":308,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37015#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp","keywords":["Cancer","HKG: 1801","Innovent Biologics","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37015#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37015","url":"https:\/\/flcube.com\/?p=37015","name":"Innovent's Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37015#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37015#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp","datePublished":"2025-07-09T06:12:51+00:00","dateModified":"2025-07-09T06:12:52+00:00","description":"China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with the approval of Dabote (fulzerasib), its novel KRAS G12C inhibitor, by Macau\u2019s health authorities. This marks the first time a China-originated KRAS G12C inhibitor has been approved in the region, underscoring Innovent's leadership in innovative oncology treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37015#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37015"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37015#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp","width":1080,"height":608,"caption":"Innovent's Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37015#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent&#8217;s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37015"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37015\/revisions"}],"predecessor-version":[{"id":37018,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37015\/revisions\/37018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37017"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}